Multivariate analysis in the development of bioequivalent tablets containing bicalutamide

References

• Andrews GP, Abu Diak OA, Jones DS. 2010. Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions. J Pharm Sci. 99:1322–1335.
   PubMed Web of Science ®Google Scholar
• Bohr A, Nascimento TL, Harmankaya N, Weisser JJ, Wang Y, Grohganz H, Rades T, Löbmann K. 2019. Efflux inhibitor bicalutamide increases oral bioavailability of the poorly soluble efflux substrate docetaxel in co-amorphous anti-cancer combination therapy. Molecules. 24:266.
   Web of Science ®Google Scholar
• Cockshot ID. 2004. Bicalutamide. Clin Pharmacokinet. 43:855–878.
   PubMed Web of Science ®Google Scholar
• Cockshot ID, Oliver SD, Young JJ, Cooper KJ, Jones DC. 1997. The effect of food on pharmacokinetics of bicalutamide (Casodex) enantiomers. Biopharm Drug Dispos. 18:499–507.
   PubMed Web of Science ®Google Scholar
• Dalvadi H, Parmar K, Yadav S. 2019. Spherical agglomeration to improve dissolution and micromeritic properties of an anticancer drug, Bicalutamide. Drug Dev Ind Pharm. 45:968–980.
   PubMed Web of Science ®Google Scholar
• Danquah M, Li F, Duke CB, Miller DD, Mahato RI. 2009. Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm. Res. 26:2081–2092.
   PubMed Web of Science ®Google Scholar
• Djuris J, Medarevic D, Krstic M, Djuric Z, Ibric S. 2013. Application of quality by design concepts in the development of fluidized bed granulation and tableting processes. J Pharm Sci. 102:1869–1882.
   PubMed Web of Science ®Google Scholar
• Dokoumetzidis A, Macheras P. 2006. A century of dissolution research: from Noyes and Whitney to the Biopharmaceutics Classification System. Int J Pharm. 321:1–11.
   PubMed Web of Science ®Google Scholar
• Dumarey M, Goodwin DJ, Davison C. 2015. Multivariate modelling to study the effect of the manufacturing process on the complete tablet dissolution profile. Int J Pharm. 486:112–120.
   PubMed Web of Science ®Google Scholar
• EMA. 2007. Questions and answers on bicalutamide 150 mg tablets. EMEA/218760/2007.
   Google Scholar
• EMEA. 2010. Guideline on the investigation of bioequivalence. Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/Corr.
   Google Scholar
• Essa EA, Elbasuony AR, Abdelaziz AE, El Maghraby GM. 2019. Co-crystallization for enhanced dissolution rate of bicalutamide: preparation and evaluation of rapidly disintegrating tablets. Drug Dev Ind Pharm. 45:1215–1223.
   PubMed Web of Science ®Google Scholar
• FDA. 2019. Bicalutamide, Dissolutions Method. [accessed 2019 Sep 28]. http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions.cfm?PrintAll=1
   Google Scholar
• FDA CDER. 1995. Guidance for industry. Immediate release dosage forms. Scale-up and post approval changes. Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation.
   Google Scholar
• FDA CDER. 1997. Guidance for industry. Dissolution testing of immediate release solid oral dosage forms.
   Google Scholar
• FDA CDER. 2000. Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release oral solid dosage forms based on a biopharmaceutics classification systems.
   Google Scholar
• Franc A, Gonec R, Petrovicova A, Zaludek B, inventors; Pliva Hrvatska, assignee. 2008. Solid oral dosage form containing bicalutamide and method of preparation. Patent WO 2008/099160 A1.
   Google Scholar
• Franc A, Muselłk J, Goněc R, Vetchý D. 2016. Biphasic dissolution method for quality control and assurance of drugs containing active substances in the form of weak acid salts. Acta Pharmaceutica. 66:139–145.
   PubMed Web of Science ®Google Scholar
• Health Canada. 2003. Accelerated deaths using Casodex® (bicalutamide) 150 mg in patients with localized prostate cancer. Dear healthcare professional letter. RA-17000445.
   Google Scholar
• Juppo AM. 1996. Porosity parameters of lactose, glucose and mannitol tablets obtained by mercury porosimetry. Int J Pharm. 129:1–12.
   Web of Science ®Google Scholar
• Kachrimanis K, Petrides M, Malamataris S. 2005. Flow rate of some pharmaceutical diluents through die-orifices relevant to mini-tableting. Int J Pharm. 303:72–75.
   PubMed Web of Science ®Google Scholar
• Kaul G, Huang J, Chatlapalli R, Ghosh K, Nagi A. 2011. Quality-by-design case study: investigation of the role of poloxamer in immediate-release tablets by experimental design and multivariate data analysis. AAPS PharmSciTech. 12:1064–1076.
   PubMed Web of Science ®Google Scholar
• Kumbhar DD, Pokharkar VB. 2013. Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: physicochemical investigations. Colloids Surf A. 416:32–42.
   Web of Science ®Google Scholar
• Le Y, Ji H, Chen JF, Shen Z, Yun J, Pu M. 2009. Nanosized bicalutamide and its molecular structure in solvents. Int J Pharm. 370:175–180.
   PubMed Web of Science ®Google Scholar
• Li C, Li C, Le Y, Chen JF. 2011. Formation of bicalutamide nanodispersion for dissolution rate enhancement. Int J Pharm. 404:257–263.
   PubMed Web of Science ®Google Scholar
• Maggio RM, Castellano PM, Kaufman TS. 2008. A new principal component analysis-based approach for testing “similarity” of drug dissolution profiles. Eur J Pharm Sci. 34:66–77.
   PubMed Web of Science ®Google Scholar
• Meer TA, Sawant KP, Amin PD. 2011. Liquid antisolvent precipitation process for solubility modulation of bicalutamide. Acta Pharm. 61:435–445.
   PubMed Web of Science ®Google Scholar
• Mercuri A, Pagliari M, Baxevanis F, Fares R, Fotaki N. 2017. Understanding and predicting the impact of critical dissolution variables for nifedipine immediate release capsules by multivariate data analysis. Int J Pharm. 518:41–49.
   PubMed Web of Science ®Google Scholar
• Merkku P, Lindqvist A-S, Leiviska K, Yliruusi J. 1994. Influence of granulation and compression process variables on flow rate of granules and on tablet properties, with special reference to weight variation. Int J Pharm. 102:117–125.
   Web of Science ®Google Scholar
• Moore JW, Flanner HH. 1996. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm. Tech. 20:64–74.
   Google Scholar
• Okáčová L, Vetchý D, Franc A, Rabišková M. 2011. Zvýšení biodostupnosti těžce rozpustných léčivých látek technologickými postupy usnadňujícími jejich rozpouštění [Increasing bioavailability of poorly water-soluble drugs by technological methods facilitating drug dissolution]. Chem Listy. 105:34–40. Czech.
   Web of Science ®Google Scholar
• Okáčová L, Vetchý D, Franc A, Rabišková M, Kratochvíl B. 2010. Zvýšení biodostupnosti těžce rozpustných léčivých látek jejich modifikací [Increasing bioavailability of poorly water-soluble drugs by their modification]. Chem. Listy. 104:21–26. Czech.
   Google Scholar
• Ortega AS, Esco JC. inventors. 2004 May 11. Bicalutamide compositions. US Patent 2005/0008691.
   Google Scholar
• Ortega AS, Esco JC. inventors. 2003 May 14. Bicalutamide forms, compositions, and processes thereof. WO2004100944A1.
   Google Scholar
• Patil AL, Pore YV, Kuchekar BS, Late SG. 2009. Solid-state characterization and dissolution properties of bicalutamide-beta-cyclodextrin inclusion complex. Die Pharmazie. 63:282–285.
   Web of Science ®Google Scholar
• Pokharkar VB, Malhi T, Mandpe L. 2013. Bicalutamide nanocrystals with improved oral bioavailability: in vitro and in vivo evaluation. Pharm Dev Technol. 18:660–666.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter W. 2009. Developing solid oral dosage forms: pharmaceutical theory & practice. Burlington (MA): Academic Press; p. 796.
   Google Scholar
• Saroj S, Rajput SJ. 2019. Facile development, characterization, and evaluation of novel bicalutamide loaded pH-sensitive mesoporous silica nanoparticles for enhanced prostate cancer therapy. Drug Dev Ind Pharm. 45:532–547.
   PubMed Web of Science ®Google Scholar
• Shohin IE, Grebenkin DY, Malashenko EA, Stanishevskii YM, Ramenskaya GV. 2016. A brief review of the FDA dissolution methods database. Dissolution Technol. 23:6–10.
   Web of Science ®Google Scholar
• Stupák I, Pavloková S, Vysloužil J, Dohnal J, Čulen M. 2017. Optimization of dissolution compartments in a biorelevant dissolution apparatus Golem v2, supported by multivariate analysis. Molecules. 22:2042.
   Web of Science ®Google Scholar
• Szafraniec J, Antosik A, Knapik-Kowalczuk J, Gawlak K, Kurek M, Szlęk J, Jamróz W, Paluch M, Jachowicz R. 2018. Molecular disorder of bicalutamide-amorphous solid dispersions obtained by solvent methods. Pharmaceutics. 10:194.
   Web of Science ®Google Scholar
• Szafraniec J, Antosik A, Knapik-Kowalczuk J, Kurek M, Syrek K, Chmiel K, Paluch M, Jachowicz R. 2017. Planetary ball milling and supercritical fluid technology as a way to enhance dissolution of bicalutamide. Int J Pharm. 533:470–479.
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G. 1998. A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 33:447–456.
   PubMed Web of Science ®Google Scholar
• Yekpe K, Abatzoglou N, Bataille B, Gosselin R, Sharkawi T, Simard JS, Cournoyer A. 2018. Developing a quality by design approach to model tablet dissolution testing: an industrial case study. Pharm Dev Technol. 23:646–654.
   PubMed Web of Science ®Google Scholar
• Zhao N, Augsburger LL. 2005. The influence of swelling capacity of superdisintegrants in different pH media on the dissolution of hydrochlorothiazide from directly compressed tablets. AAPS Pharmscitech. 6:E120–E126.
   PubMed Web of Science ®Google Scholar